BGI Genomics Co Ltd
SZSE:300676
BGI Genomics Co Ltd
Income from Continuing Operations
BGI Genomics Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BGI Genomics Co Ltd
SZSE:300676
|
Income from Continuing Operations
¥64.5m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Income from Continuing Operations
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Income from Continuing Operations
-¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Income from Continuing Operations
¥1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Income from Continuing Operations
¥7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
35%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Income from Continuing Operations
¥1.3B
|
CAGR 3-Years
62%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is BGI Genomics Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
64.5m
CNY
Based on the financial report for Mar 31, 2024, BGI Genomics Co Ltd's Income from Continuing Operations amounts to 64.5m CNY.
What is BGI Genomics Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-31%
Over the last year, the Income from Continuing Operations growth was -88%. The average annual Income from Continuing Operations growth rates for BGI Genomics Co Ltd have been -70% over the past three years , -31% over the past five years .